MaaT Pharma presents positive data for MaaT013 at 18 months at EBMT 2024 showing a clear advantage in terms of overall survival in aGvHD in its compassionate access program:
• Positive efficacy and safety results in 140 patients treated with lead product MaaT013 in acute graft-versus-host disease under MaaT Pharma’s Compassionate Access Program (EAP).
• Gastrointestinal overall response rate (GI-ORR) of 52% observed on day (D) 28.
• Long-term survival data at 18 months with 42% overall survival (OS) in all patients and 58% in patients responding to MaaT013.
• Used in 3rd line, MaaT013 presents a high and durable response rate (with 63% GI-ORR at D28 and 53% at D56), resulting in the highest survival in this patient population compared to reported data in the literature (Abedin et al., 2021).
• A pivotal Phase 3 trial evaluating MaaT013 (ARES trial – NCT04769895; n=75) in patients with GI-aGvHD refractory to corticosteroids and ruxolitinib is ongoing with the primary endpoint expected in mid-Q4 2024 .
To receive all financial information from MaaT Pharma in real time and for any questions, you can contact us via the following address: [email protected]